Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585246 · ClinicalTrials.gov registry record · Phase 1
Saw Palmetto: Symptom Management for Men During Radiation Therapy
A Phase 1 study of Prostate Cancer, sponsored by Michigan State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 6
- Study locations
NCT01585246 is a Phase 1 study of Prostate Cancer that has completed, run by Michigan State University. The registered enrollment target is 48 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT01585246, a Phase 1 study of Prostate Cancer, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 6
- Study locations
Study Summary
The aim of this study is to test whether Saw Palmetto, is useful in preventing or reducing the side effects for men undergoing radiation therapy for prostate cancer. Urinary symptoms will be recorded each week, as well as assessment of quality of life through: 1) Physical Well-Being 2) Social/Family Well-being 3) Emotional Well-Being, and 4) Functional Well-Being.
Conditions Studied
Interventions
- DRUG Saw Palmetto
- DRUG soybean oil soft gel
Study Locations (6)
Michigan
- Allegiance Health - Jackson
- McLaren Greater Lansing - Lansing
- Sparrow Cancer Center - Lansing
- McLaren Macomb - Mount Clemens
- McLaren Central Michigan - Mount Pleasant
- St. Joseph Mercy Oakland Hospital - Pontiac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585246
The ClinicalTrials.gov registry entry for NCT01585246 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Michigan State University, which has 120 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Saw Palmetto is the first listed.
NCT01585246 reports 6 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01585246 about?
NCT01585246 is a clinical study titled "Saw Palmetto: Symptom Management for Men During Radiation Therapy". The aim of this study is to test whether Saw Palmetto, is useful in preventing or reducing the side effects for men undergoing radiation therapy for prostate cancer. Urinary symptoms will be recorded each week, as well as assessment of quality of life through: 1) Physical Well-Being 2) Social/Family...
What is the current status of trial NCT01585246?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-10. Estimated completion is 2015-04.
What conditions does trial NCT01585246 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01585246?
The interventions under investigation include: Saw Palmetto (DRUG), soybean oil soft gel (DRUG).
Who is sponsoring clinical trial NCT01585246?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01585246 being conducted?
This trial has 6 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.